Diversion Control Division, US Department of Justice, Drug Enforcement Administration

RESOURCES > Federal Register Notices > Notices - 2001 > Denial of Petition

Notices - 2001

References

Adams, I.B., and Martin, B.R. Cannabis: Pharmacology and toxicology in animals and
           humans. Addiction 1996, 91(11):1585-1614.
Agurell, S., Dewey, W.L., and Willett, R.E., eds. The Cannabinoids: Chemical,
           Pharmacologic, and Therapeutic Aspects. New York: Academic Press, 1984.
Agurell, S.; Halldin, M.; Lindgren, J.E.; Ohlsson, A.; Widman, M.; Gillespie, H.; and
           Hollister, L. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986, 38(1), 21-43.
Ameri, A. The effects of cannabinoids on the brain. Progress in Neurobiology 1999, 58(4),
            315-348.
Balster, R.L., Prescott, W.R.,) \9\-Tetrahydrocannabinol discrimination in rats as a model
           for cannabis intoxication. Neurosci. & Biobehav. Rev. 1992, 16(1), 55-62.
Barnett, G.; Licko, V.; and Thompson, T. Behavioral pharmacokinetics of marijuana.
           Psychopharmacology 1985, 85(1), 51-56.
Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment
           for marijuana dependence. Addiction 1999, 94(9):1311-22 Community Epidemiology Work Group, National Institutes of Health, National Institute on Drug Abuse, Epidemiologic Trends in Drug Abuse, Volume I: Highlights and Executive Summary, June 2000, http://www.nida.nih.gov/CEWG/pubs.html
Department of Health and Human Services. Announcement of the Department of Health
           and Human Services Guidance on Procedures for the Provision of Marijuana for Medical Research. May 21, 1999. (http://grants.nih.gov/grants/guide/notice-files/not99-091.html).
Drug Abuse Warning Network. Year-End 1999 Emergency Department Data from the
           Drug Abuse Warning Network. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. National Clearinghouse for Alcohol and Drug information. Rockville, MD.
Drug Abuse Warning Network. Annual Medical Examiner Data 1998. Department of
           Health and Human Services. Substance Abuse and Mental Health Services Administration. National Clearinghouse for Alcohol and Drug information. Rockville, MD.
DSM-IV-TR 2000: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
           Text Revision 4th Edition--Text Revision American Psychiatric Association, Publisher: American Psychiatric Press, Incorporated, Pub. Date: July 2000, Edition Desc: 4th Edition--Text Revision.
Dewey, W. L., Martin, B. R., May, E. L. Cannabinoid stereoisomers: pharmacological
           effects. In Smith, D. F. (Ed.) CRC Handbook of stereoisomers: drugs in psychopharmacology, 317-326 (Boca Raton, FL, CRC Press), 1984. 
Fried, P. A., Watkinson, B. 36- and 48-month neurobehabioral follow- up of children
           prenatally exposed to marijuana, cigarettes and alcohol. J. Dev. Behav. Pediatr. 1987, 8, 318-326.
Fried, P. A., Watkinson, B., Gray, R. A follow-up study of attentional behavior in 6-year-old
           children exposed prenatally to marihuana, cigarettes and alcohol. Neurotoxicol. Teratol. 1992, 14, 299-311. 
Fried, P. A., Watkinson, B., Gray, R. Differential effects on cognitive functioning in 9- to
            12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol. Teratol. 1998, 20(3), 293- 306.
French, E.D. Delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through
           activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 1997, 226, 159-162.
Fung, M., Gallagher, C., Machtay, M. Lung and aeo-digestive cancers in young marijuana
           smokers. Tumori 1999, 85 (2), 140-142. 
Galiegui, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.;
           Bouaboula, M; Shire, D.; Le Fur, g.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995, 232(1), 54-61.
Gaoni, Y., Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent
           of hashish. J. Am. Chem. Soc. 1964, 86, 1646-1947. 
Gerard, C. M., Mollereau, C., Vassart, G., Parmentier, M. Molecular cloning of a human
           cannabinoid receptor which is also expressed in testis. : Biochem J. 1991, 279, 129-34.
Gessa, G.L., Melis, M., Munoni, A.L., Diana, M. Cannabinoids activate mesolimbic
           dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998, 341(1), 39-44. 
Graham, J.D.P., ed. Cannabis and Health. New York: Academic Press, 1976.
Griffith, D. R., Azuma, S. D., Chasnoff, I. J. Three-year outcome of children exposed
           prenatally to drugs. J. Am. Acad. Child Adolesc. Psychiatry 1994, 33, 20-27. 
Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms
           following smoked marijuana in humans. Psychopharmacology (Berl) 1999, 141(4):395-404.
Hanus, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee,
           R.G., Roos, R. A., Mechoulam, R., Fride, E. HU-308: a specific agonist for CB(2), a peripheral Cannabinoid receptor. Proc. Natl. Acad. Sci. USA 1999, 96, 14228-33.
Harvey, D.J., ed. Satellite Symposium on Cannabis (3rd: 1984: Oxford, England)
           Marihuana '84: Proceedings of the Oxford Symposium on Cannabis. Washington, DC: IRL Press, 1985. 
Herkenham, M. Cannabinoid receptor localization in brain: Relationship to motor and
           reward systems. In: Kalivas, P.W., and Samson, H.H., eds. The neurobiology of drug and alcohol addiction. Ann N Y Acad Sci 1992, 654, 19-32.
Herkenham, M., Lynn, A.B., Little, M.D., Johnson, M.R., Melvin, L.S., de Costa, B.R., Rice,
           K.C. Cannabinoid receptor localization  in Brain. Proc. Natl. Acad. Sci. USA. 1990, 87, 1932-1936.
Herning, R.I.; Hooker, W.D.; and Jones, R.T. Tetrahydrocannabinol content and 
           differences in marijuana smoking behavior. Psychopharmacology 1986, 90(2):160-162.
Hively, R.L., Mosher, W.A., Hoffman, F.W. Isolation of trans-)9- tetrahydrocannabinol from
           marihuana. J. Am. Chem. Soc. 1966, 88,  1832-1833.
Hollister, L.E. Health aspects of cannabis. Pharmacological Rev. 1986, 38, 1-20.
Hollister, L.E. Cannabis. (Literature review). Acta Psychiatr Scand (Suppl) 1988, 78,
           108-118.
Huestis, M.A., Sampson, A.H., Holicky, B.J., Henningfield, J.E., Cone, E.J.
           Characterization of the absorption phase of marijuana smoking. Clin. Pharmacol. Ther. 1992a, 52, 31-41. 
Huestis, M.A.; Henningfield, J.E.; and Cone,
           E.J. Blood Cannabinoids. 1. Absorption of THC and formation of 11- OH-THC and THC COOH during and after smoking marijuana. J Anal Toxicol 1992b, 16(5), 276-282.
          
[[Page 20053]]

Johansson, E.; Halldin, M.M.; Agurell, S.; Hollister, L.E.; and Gillespie, H.K. Terminal
           elimination plasma half-life of delta 1- tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur J Clin Pharmacol 1989, 37(3), 273-277.
Jones, R.T.; Benowitz, N.L.; and Herning, R.I. Clinical relevance of cannabis tolerance and
           dependence. J Clin Pharmacol 1981, 21,143S- 152S.
Koob, G.F. Neural mechanisms of drug reinforcement. Ann. N Y Acad Sci 1992, 654,
           171-191.
Lane JD, Phillips-Bute BG. Caffeine deprivation affects vigilance performance and mood.
           Physiol Behav 1998 65, 171-5.
Lemberger L., Rubin A. The physiologic disposition of marihuana in man, Life Sci.
           1975,17, 1637-42.
 Lemberger L., Silberstein, S.D., Axelrod, J., Kopin, I.J. Marihuana: studies on the
           disposition and metabolism of delta-9- tetrahydrocannabinol in man. Science 1970, 170, 1320-1322.
Lemberger L., Weiss, J.L., Watanabe, A.M., Galanter, I.M., Wyatt, R.J., Cardon, P. V.
           Delta-9-tetrahydrocannabinol: temporal correlation of the psychological effects and blood levels after various routes of administration. New Eng. J. Med. 1972a, 286(13), 685-688.
Lemberger, L., Crabtree, R.E., Rowe, H.M. 11-Hydroxy-)9-tetrahydrocannabinol:
           pharmacology, disposition and metabolism of a major metabolite of marihuana in man. Science 1972b, 177, 62-63.
 Martin, B.R.; Mechoulam, R., Razdan, R.K. Discovery and characterization of 
           endogenous cannabinoids. Life Sci. 1999, 65, 573-595.
Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., Bonner, T.I. Structure of a
           cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346, 561-564.
Mechoulam, R. Cannabinoid chemistry. In Mechoulam, R. (ED.) Marijuana, pp.2-88 (New
           York, NY, Academic Press, Inc.), 1973. 
Monitoring the Future. National Results on Adolescent Drug Use. Overview of 1999 Key
           findings, 1999. Department of Health and Human services. National Institute on Drug Abuse. Rockville, MD. (http://monitoringthefuture.org) 
National Institutes of Health (NIH). Workshop on the medical Utility of Marijuana,
           February 19-20, 1997.
NHSDA. Summary of Findings from the 1999 National Household Survey on Drug Abuse.
           Office of Applied Studies. Department of Health and Human services. Substance Abuse and Mental Health Services Administration. National Clearinghouse for Alcohol and Drug information. Rockville, MD. 
Office of National Drug Control Policy. The National Drug Control  Strategy: 2000 Annual
           Report. Superintendent of Documents, Mail  Stop: SSOP, Washington, DC. 
Oviedo, A., Glowa, J., Herkenham, M. Chronic cannabinoid administration alters
           cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res. 1993, 616, 293-302. 
Rinaldi-Carmona, M., Barth F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez,
           S., Maruani, J., Neliat, G., Caput, D., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 1994, 350, 240-244.
Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, 
           Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Breliere JC, Le Fur GL, SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 1998 , 284(2), 644-50.
Rodriguez de Fonseca F, Gorriti, M.A., Fernandez-Ruiz, J.J., Palomo, T., Ramos, J.A.
           Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinoil treatment. 
Phamacol. Biochem. Behav. 1994, 47 (1), 33-40. Ross, S.A. and ElSohlyy, M.A.
           Constituents of Cannabis Sativa L. XXVIII. A review of the natural constituents:1980-1994. Zagazig J. Pharm. Sci. 1995, 4 (2), 1-10.
Sanudo-Pena M.C., Tsou, K., Delay, E.R., Hohman, A.G., Force, M., Walker, J.M.
           Endogenous cannabinoids as an aversive or counter- rewarding system in the rat. Neurosci. Lett., 223, 125-128, 1997.
Treatment Episode Data Set (TEDS): 1993-1998. National Admissions to Substance
           Abuse Treatment Services. Department of Health and Human services. Substance Abuse and Mental Health Services Administration. National Clearinghouse for Alcohol and Drug information. Rockville, MD.
Wesson, D.R.; Washburn, P. Current patterns of drug abuse that involve smoking. In
           Research Findings on Smoking of Abused Substances, Chiang, C.N.; Hawks, R.L. (ED.) NIDA Research Monograph, 99:5-11, 1990.

Previous Page |  Next Page

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility